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Abstract
EFSA has asked the Panel on Nutrition, Novel Foods and Food Allergens (NDA) to update the guidance
on the scientiﬁc requirements for health claims related to physical performance published in 2012. The
update takes into account the experience gained by the NDA Panel with the evaluation of additional
health claim applications, changes introduced to the general scientiﬁc guidance for stakeholders for
health claims applications and information collected from a grant launched in 2014 which aimed at
gathering information in relation to claimed effects, outcome variables and methods of measurement
in the context of the scientiﬁc substantiation of health claims. The guidance is intended to assist
applicants in preparing applications for the authorisation of health claims related to muscle function
and physical performance. The draft guidance was subject to public consultation from 16 July to 2
September 2018. This document supersedes the guidance on the scientiﬁc requirements for health
claims related to physical performance published in 2012. It is intended that the guidance will be
further updated as appropriate in the light of experience gained from the evaluation of health claims.
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Summary
The European Food Safety Authority (EFSA) has asked the Panel on Nutrition, Novel Foods and
Food Allergens (NDA) to revise the guidance on the scientiﬁc requirements for health claims related to
physical performance published in 2012.
Since then, the NDA Panel has completed the evaluation of Article 13.1 claims (except for claims
put on hold by the European Commission) and has evaluated additional health claim applications
submitted pursuant to Article 13(5) in the area covered by this guidance. In addition, the NDA
Panel has developed the general scientiﬁc guidance for stakeholders for health claims applications
which addresses general issues that are common to all health claims. To further assist applicants, EFSA
launched in 2014 a grant which aimed at gathering information in relation to claimed effects, outcome
variables and methods of measurement in the context of the scientiﬁc substantiation of health claims.
The information collected helped the NDA Panel in updating the present guidance.
This guidance is intended to assist applicants in preparing applications for the authorisation of
health claims related to muscle function and physical performance. It focuses on key issues,
particularly:
• claimed effects which are considered to be beneﬁcial physiological effects,
• deﬁnition of the target population for which the claim is intended;
• characteristics of the human intervention studies which can provide evidence for the scientiﬁc
substantiation of speciﬁc claims addressed in this guidance (e.g. appropriate outcome variables
and methods of measurement, suitable study group(s), suitable controls).
This guidance does not intend to:
a) provide an exhaustive list of beneﬁcial physiological effects and studies/outcome variables
which could be acceptable for claim substantiation, or
b) address potential health relationships and related outcome variables/methods of measurement
which have not yet been considered by the Panel in the context of a particular application.
The draft guidance was released for public consultation (from 16 July to 2 September 2018) to
gather views from scientiﬁc communities and stakeholders before ﬁnalisation. This guidance
supersedes the guidance on the scientiﬁc requirements for health claims related to physical
performance published in 2012. It is intended that the guidance will be further updated as appropriate
in the light of experience gained from the evaluation of health claims in this area.
Guidance for health claims on muscle function and physical performance
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Background and Terms of Reference as provided by EFSA
Background
Regulation (EC) No 1924/20061 harmonises the provisions related to nutrition and health claims
and establishes rules governing the Community authorisation of health claims made on foods.
According to the Regulation, health claims should only be authorised for use in the Community after a
scientiﬁc assessment of the highest possible standard to be carried out by EFSA.
Owing to the scientiﬁc and technical complexity of health claims, the EFSA Panel on Dietetic
Products, Nutrition and Allergies (NDA)2 has placed considerable effort into developing scientiﬁc criteria
for the substantiation of health claims, and has published guidance on the scientiﬁc substantiation of
health claims since 2007.3
Over the last number of years, the NDA Panel has gained considerable experience in the evaluation
of health claim applications. To further assist applicants seeking approval of health claims, EFSA
launched in 2014 a grant (GP/EFSA/NUTRI/2014/01) which aimed at gathering information in relation
to claimed effects, outcome variables and methods of measurement in the context of the scientiﬁc
substantiation of health claims. The information collected4 was to help inform the NDA Panel and serve
as a basis for further guidance to applicants.
In this context, note is taken of the need to adapt the existing guidance on the scientiﬁc
requirements for health claims3 to the new scientiﬁc and technical developments in speciﬁc areas,
taking into account lessons learned from the evaluation of health claim applications and the
information collected from the grant.
To this end, the NDA Panel is asked to update the existing guidance on the scientiﬁc requirements
for health claims related to physical performance published in 2012.5
Terms of Reference
The NDA Panel is requested by EFSA to update the existing guidance on the scientiﬁc requirements
for health claims related to physical performance.
The guidance document shall clarify and address the scientiﬁc and technical developments in this
area, taking into account the experience gained by the NDA Panel with the evaluation of health claims
and the information collected from the grant.
The draft guidance shall be released for public consultation prior to ﬁnalisation, and shall be revised
taking into account the comments received during the public consultation before adoption by the NDA
Panel. A technical report on the outcome of the public consultation shall be published.
1. Introduction
The Guidance on the scientiﬁc requirements for health claims related to physical performance
published in 2012 (EFSA NDA Panel, 2012c) laid down recommendations on speciﬁc issues that need
to be addressed in applications submitted for the substantiation of health claims in this area. Since
then, the Panel has evaluated additional health claim applications related to muscle function and
physical performance.
Among the health claim applications submitted to EFSA as of 8/2/2018 (n = 490), 12 were relevant
to this guidance: ﬁve were withdrawn during the evaluation, and seven were evaluated/ﬁnalised by the
Panel. Among those ﬁnalised, three were evaluated by the Panel with a favourable outcome and all
three referred to claims other than those based on the essentiality on nutrients: two were on muscle
function and one on physical performance (Appendix A).
Examples of health claims evaluated by the Panel with a favourable outcome (under Article 13(1)
and applications under Article 13(5)) will be used to provide guidance to applicants on the scientiﬁc
requirements for the substantiation of health claims in these areas, whereas examples of claims
evaluated by the NDA Panel with an unfavourable opinion will be used to illustrate the shortcomings
that prevented the substantiation of these claims.
1 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health
claims made on foods. OJ L 404, 30.12.2006, p. 9–25.
2 As from 1 July 2018, the NDA Panel has been renamed as EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA).
3 https://www.efsa.europa.eu/en/applications/nutrition/regulationsandguidance
4 https://www.efsa.europa.eu/en/supporting/pub/1272e
5 https://www.efsa.europa.eu/en/efsajournal/pub/2817
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The information collected from the grant (GP/EFSA/NUTRI/2014/01)4 launched by EFSA in 2014,
which aimed at gathering information in relation to claimed effects, outcome variables and methods of
measurement in the context of the scientiﬁc substantiation of health claims, was considered by the
Panel for updating this guidance.
2. Objectives and scope
This guidance is intended to assist applicants in preparing applications for the scientiﬁc
substantiation of health claims related to muscle function and physical performance. The document
focuses on:
• examples of claimed effects which are considered to be beneﬁcial physiological effects;
• deﬁnition of the target population for which the claim is intended;
• characteristics of human intervention studies which can provide evidence for the scientiﬁc
substantiation of speciﬁc claims addressed in this guidance (e.g. appropriate outcome variables
and methods of measurement, suitable study group(s), suitable controls).
Issues related to scientiﬁc substantiation that are common to all health claims (e.g. principles
applied for claims based on the essentiality of nutrients vs. claims other than those based on the
essentiality of nutrients, aspects related to the characterisation of the food/constituent and to the
characterisation of the claimed effect, examples of the evidence required for the substantiation of
claims, criteria for the identiﬁcation of pertinent human studies, extrapolation of the results from the
study group to the target population) are addressed in the General scientiﬁc guidance for stakeholders
on health claims applications (EFSA NDA Panel, 2016a) and will not be reiterated in this document.
This document has been developed based on previously published scientiﬁc opinions of the NDA
Panel on health claims related to muscle function and physical performance. Thus, it represents the
views of the NDA Panel based on the experience gained from the evaluation of health claims in these
areas.
It is not intended that the document should:
a) include an exhaustive list of beneﬁcial effects and studies/outcome variables which are
acceptable for claims substantiation, or
b) address potential health relationships and related outcome variables/methods of measurement
which have not been considered by the Panel yet in the context of a particular application.
This is because deﬁning the conditions under which health relationships and outcome variables/
methods of measurement for claimed effects may be acceptable is possible only in the context of
speciﬁc applications, which are often unique and technically complex. For example, health relationships
and outcome variables which may be acceptable in the context of a particular application may not be
so in the context of another application with, for example, a different target population. The guidance
rather presents examples drawn from evaluations already carried out to illustrate the approach of the
Panel. This guidance will be kept under review and will be amended and updated in the light of
experiences gained from the evaluation of additional health claim applications in this area.
This guidance should be read in conjunction with the General scientiﬁc guidance for stakeholders
on health claim applications (EFSA NDA Panel, 2016a), the Scientiﬁc and technical guidance for the
preparation and presentation of a health claim application (EFSA NDA Panel, 2017), Regulation (EC)
No 1924/2006 on nutrition and health claims made on foods,6 the Guidance on the implementation of
Regulation (EC) No 1924/2006 (Standing Committee on the Food Chain and Animal Health, 2007),
Commission Regulation (EC) No 353/20087, the Commission Implementing Decision of 24 January
20138 and future guidelines and regulations, as applicable.
6 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health
claims made on foods. OJ L 404, 30.12.2006, p. 9–25. Available at http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=
CONSLEG:2006R1924:20100302:en:PDF
7 Commission Regulation (EC) No 353/2008 of 18 April 2008 establishing implementing rules for applications for authorisation of
health claims as provided for in Article 15 of Regulation (EC) No 1924/2006 of the European Parliament and of the Council
(Text with EEA relevance) (OJ L 109, 19.4.2008, p. 11): http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:
2008R0353:20091221:EN:PDF
8 Commission Implementing Decision of 24 January 2013 adopting guidelines for the implementation of speciﬁc conditions for
health claims laid down in Article 10 of Regulation (EC) No 1924/2006 of the European Parliament and of the Council. OJ L 22,
25.1.2013, p. 25–28. Available at http://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32013D006
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3. Deﬁnition of terms
During the scientiﬁc evaluation of health claims in the area of physical performance over the last 10
years, and in preparation for the update of this guidance document, the Panel has noticed the lack of
consensus with respect to the terminology used in sport science (and practice) to describe different
types of ‘physical activities’ or ‘exercises’ with respect to:
a) their duration, ‘intensity’ and the effort required to perform them, and
b) the methods and units of measurement of such effort.
Whereas a number of publications have proposed ways to standardise both nomenclature and
‘exercise’ classiﬁcation depending on the type, ‘intensity’, duration and predominant metabolic
pathways contributing to energy supply, they contradict each other in several ways (Caspersen et al.,
1985; Howley, 2001; Chodzko-Zajko et al., 2009; Norton et al., 2010; Garber et al., 2011; Fisher and
Smith, 2012; Chamari and Padulo, 2015; Winter et al., 2016).
Several terms for which there is no consensual deﬁnition have been used by the Panel in the
context of speciﬁc health claim evaluations. Some of these terms (e.g. endurance capacity, strenuous
exercise, short-term high-intensity exercise) have rather been deﬁned for the purpose of the speciﬁc
assessment (e.g. to establish conditions of use for the claim). Some other terms (e.g. muscle fatigue)
had not been deﬁned, assuming that they had a precise meaning and were well understood in the
research ﬁeld.
For the purpose of this guidance, and within the context of the scientiﬁc evaluation of health claims
in the area of muscle function and physical performance, the Panel provides a common deﬁnition of
terms to help communication between applicants, EFSA and risk managers. The Panel also indicates
the information that should be provided in future applications to characterise the claimed effect, the
target population and the conditions of use for the claim whenever common terms used in the
scientiﬁc literature may lead to misinterpretation.
For the purpose of this guidance, and having regard of the scientiﬁc references cited above:
Physical activity is deﬁned as any bodily movement produced by skeletal muscles, which
requires energy expenditure. Physical activity broadly encompasses physical exercise, sports
and physical activities done as part of daily living, occupation, leisure and active transportation.
Physical ﬁtness is a set of attributes that people have or achieve that relates to the ability to
perform physical activity (e.g. cardiorespiratory endurance, muscular endurance, muscular
strength, body composition, ﬂexibility, agility, balance, coordination, speed, power, reaction
time). The degree to which people have these attributes can be measured with speciﬁc tests.
Physical exercise is deﬁned as a subset of physical activity that is planned and structured,
and has as a ﬁnal or an intermediate objective the improvement or maintenance of one or
more components of physical ﬁtness.
Resistance exercise (training) is a speciﬁc type of physical exercise designed to increase
muscular strength, power and/or endurance. It can vary in the resistance, speed, the number
of times the resistance is moved in a single group (set) of exercise, the number of sets done
and the rest interval provided between sets.
Intensity/load, frequency, duration and mode/type are used to describe the characteristics
of an exercise to bring about a particular response. Their combination affects the volume of the
exercise and the predominant metabolic pathways and substrates that are involved.
Intensity/load refers to the effort required by an individual to complete a given physical
activity or exercise. Objective measures of exercise intensity are usually expressed as relative
values (e.g. %HRmax, %HRR,
9 %VO2max, %VO2R
10). Exercise intensity has also been classiﬁed
using subjective measures, i.e. relative to the subject’s perception of effort, using the Borg’s
Rating of Perceived Exertion (RPE) scale. For resistance training, ‘intensity’ refers to the
amount of resistance (load). The one repetition maximum (1RM), which is the greatest weight
that can be lifted or displaced one time in good form, is relevant for dynamic measurements,
whereas the maximal voluntary contraction (MVC) is relevant for isometric measurements.
Objective measures of load are usually expressed as relative values (e.g. %1RM, %MVC).
9 HRR =HRmax  resting HR
10 VO2R = VO2max resting VO2
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Frequency in training programmes is described as the number of activity sessions per day,
week or month.
Duration refers to the number of minutes of activity in each exercise session (and to the
duration of each interval within a session for interval training).
The mode/type refers to the type of exercise performed (e.g. cycling, running, swimming,
weight-lifting, etc.) and to whether this is intermittent (e.g. repeated bouts, sprints, interval
training) or continuous.
Whereas several classiﬁcations of physical exercise have been proposed with respect to their
intensity and duration, the main metabolic pathways involved and/or the type of physical ﬁtness
targeted,11 the Panel notes that the nomenclature in this ﬁeld is not harmonised. Therefore, in the
context of claims substantiation, the claimed effect (e.g. the testing conditions under which the food/
constituent may affect performance) must be described (characterised) in terms of mode/type of
exercise, intensity/load (using objective measures and expressed as relative values) and duration (in
minutes). The characterisation of training programmes which may be part of the conditions of use for
the claim (e.g. if the efﬁcacy of food/constituent on performance is only observed when its
consumption is coupled to a training program) requires also information on frequency. The
characterisation of physical exercises for the substantiation of health claims on physical performance
and physical capacity is addressed in Section 4.2.2.
Muscle contraction is the activation of tension-generating sites within muscle ﬁbres and can
be concentric or eccentric.
Muscle strength refers to the (maximum) amount of external force that a skeletal muscle (or
muscle group) can exert. It may be expressed as MVC for isometric measurements and as the
1RM for dynamic measurements.
Endurance is the ability to sustain a physical activity or exercise over a period of time.
Muscle endurance refers to the ability of muscle groups to exert and maintain an external
force for a number of repetitions or successive exertions against a constant resistance.
Muscle fatigue is deﬁned as any exercise-induced reduction in the maximal capacity to
generate force or power output, or in the capacity to maintain a predeﬁned force or power
output.
Exercise-induced muscle soreness is an aching sensation following muscular exertion that
can be acute (i.e. the immediate ache perceived by the athlete while or immediately after
exercise) or delayed. Delayed-onset muscle soreness (DOMS) generally occurs following
unaccustomed muscular exertion and is mainly related to eccentric muscular efforts. Muscle
soreness can vary from mild discomfort to incapacitating pain depending on the intensity,
volume and novelty of the exercise.
Exercise-induced muscle damage refers to the disruption of muscle ﬁbres during exercise
which may be associated to a reduction of muscle function. Muscle damage may lead to pain
and soreness, but these may also occur in the absence of muscle damage.
Mechanical work is the amount of energy transferred by a force acting over a certain
distance.
Power relates to the rate at which mechanical work can be performed.
Physical performance is the ability to complete certain physical tasks. An increase in
physical performance refers to completion of a given physical task with higher intensity, and
therefore faster or with a higher power output.
Physical capacity is the ability to continue a physical activity despite increasing physical or
psychological stress, and refers to the exercise time to fatigue when exercising at predeﬁned
conditions (e.g. a given load, intensity or speed).
Appropriate outcome variables to assess physical capacity and physical performance in human
intervention studies are discussed in Section 4.2.2.
The terms endurance capacity and endurance performance have been used by the Panel in
previous guidance documents and scientiﬁc opinions to denote physical capacity and performance
assessed during physical exercises of ‘moderate’ intensity (generally < 80% VO2max). These terms will
11 For example: endurance, cardiorespiratory, ﬂexibility, and neuromuscular exercise; ‘aerobic’ and ‘anaerobic’ exercise;
sedentary, light, moderate, vigorous and high-intensity exercise; all-out (maximal) efforts: ‘explosive’, ‘high intensity’,
‘endurance intensive efforts’.
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only be used in the present guidance to describe examples of previous evaluations for illustration
purposes.
The target population for the claim should be characterised in terms of age and level of physical
ﬁtness (or level of training) if: (a) these characteristics are thought to affect the relationship between
the intake of the food/constituent and the claimed effect, and/or (b) if the studies provided for the
substantiation of the claim have been conducted in speciﬁc study groups (e.g. elderly male subjects)
and the extrapolation of the results to the general (healthy) population cannot be justiﬁed.
The Panel notes, however, that there is no consensus on the deﬁnition of terms such as
‘moderately active individuals’, ‘recreationally active individuals’, ‘athletes’ or ‘elite athletes’. Similarly,
common terms used to deﬁne age groups (e.g. adolescents, elderly subjects) may correspond to
different age ranges. Therefore, for the purpose of characterising the target population in the area of
health claims related to muscle function and physical performance, age and/or level of physical ﬁtness
(or training) should be indicated as precisely as possible whenever these characteristics are important
to establish conditions of use for the claim. For example, the level of physical ﬁtness (or level of
training) of the target population would be better described by characteristics such as the intensity/
load, frequency, duration, and mode/type of the physical exercise being performed on regular basis,
while years (or age ranges) would be more appropriate to describe age.
4. Assessment
4.1. Function claims based on the essentiality of nutrients
Several health claims related to essential nutrients have been scientiﬁcally substantiated based on
the principle of the essentiality of these nutrients12: (i) the nutrient is required for normal human body
function(s), i.e. it has an essential mechanistic role in a metabolic function and/or it has the ability to
reverse clinical signs and symptoms of its deﬁciency; (ii) the nutrient cannot be synthesised by the
body or cannot be synthesised in amounts which are adequate to maintain normal body function(s)
and (iii) the nutrient must be obtained from a dietary source. For these claims (described below in this
sections), the Panel did not review the primary scientiﬁc studies submitted and it did not weigh the
evidence.
4.1.1. Claims on muscle function
The improvement, maintenance or reduced loss of muscle function (contraction) is considered
a beneﬁcial physiological effect. Failure to increase muscle mass during growth and development,
and the loss of muscle mass at any age, will impair muscle function (e.g. muscle strength and
power). Faster recovery of normal muscle function after exercise is also considered a beneﬁcial
physiological effect.
Claims on the well-established role of some minerals such as sodium (EFSA NDA Panel, 2011g),
potassium (EFSA NDA Panel, 2010h), magnesium (EFSA NDA Panel, 2009c) and calcium (EFSA NDA
Panel, 2009a) on the maintenance of normal muscle function (contraction) have been evaluated
by the Panel with a favourable outcome. The target population for these claims was the general
healthy population. Conditions of use were established on the basis that any signiﬁcant amount of the
essential nutrient in the diet will contribute to the claimed effect (i.e. conditions of use were linked to
nutrition claims).
A claim on dietary protein and growth or maintenance of muscle mass was also evaluated by
the Panel with a favourable outcome (EFSA NDA Panel, 2010a). The Panel considered that the role of
dietary protein in the growth (during development) and maintenance (after adolescence) of whole
body lean body mass, including muscle mass, was well-established. Maintenance of lean body mass
can be achieved if (protein) nitrogen intake is equal to or above (protein) nitrogen losses over a period
of time. It is well documented that protein intake is necessary to maintain nitrogen (protein) balance
as nitrogen is lost from the body primarily via the urine, but also in small amounts via faeces, sweat,
skin, hair and nails. Similarly, maintenance of muscle mass is typically achieved if mean muscle protein
synthesis rate is equal to mean muscle protein breakdown rate over a period of time. Protein intakes
within the Dietary Reference Values (DRVs) allow for the growth and maintenance of lean body mass,
including muscle mass, for normal protein turnover, and for muscle recovery after physical exercise.
The target population for this claim was the general healthy population. Conditions of use were
12 See General scientiﬁc guidance for stakeholders on health claim applications, Section 6.1.
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established on the basis that any signiﬁcant amount of protein in the diet will contribute to the claimed
effect (i.e. conditions of use were linked to nutrition claims).
For the scientiﬁc substantiation of health claims related to speciﬁc protein sources or protein
components on measures of muscle function (i.e. muscle mass and muscle strength), see
Section 4.2.1.
4.2. Function claims other than those based on the essentiality of
nutrients
4.2.1. Claims on muscle function
Function claims other than those based on the essentiality of nutrients have been submitted on
muscle strength, rather than on muscle function. Noting that muscle strength is a speciﬁc aspect of
muscle function, claims may refer to muscle strength speciﬁcally, rather than to muscle function in
general. In this context, outcome variables that are appropriate to assess muscle strength in human
studies include 1RM and isometric strength tests (e.g. 1RM weight lifting (bench press), 1RM leg press,
1RM knee extension, 1RM biceps curl, isometric handgrip strength, isokinetic knee extension torque).
Owing to these single outcome variables of muscle strength generally assessing speciﬁc muscle
groups, the evaluation of general muscle strength requires the use of multiple outcome variables in
combination (e.g. assessing muscle strength in the upper and lower body). Outcome variables related
to motor functional performance (e.g. gait speed, timed-get-up-and-go test, stair climbing) are not
direct measures of muscle strength. The use of these outcome variables in the scientiﬁc substantiation
of claims on physical performance is discussed in Section 4.2.2.1.
Outcome variables related to body composition (e.g. whole-body lean body mass, muscle mass)
or muscle structure (e.g. muscle shape, number and type of muscle ﬁbres, muscle damage, muscle
tissue repair) are not direct measures of muscle function. However, since changes in one or more of
these outcome variables may contribute to the improvement, maintenance or reduced loss of muscle
function, they could be used as supportive evidence for the scientiﬁc substantiation of claims on
muscle function/strength. Invasive (e.g. muscle biopsy) and non-invasive (e.g. high-frequency
ultrasound, magnetic resonance imaging) techniques can be used to assess different components of
muscle structure. Claims related to changes in body composition have been addressed in the ‘Guidance
on the scientiﬁc requirements for health claims related to appetite ratings, weight management, and
blood glucose concentrations’ (EFSA NDA Panel, 2012d). Measures of muscle protein turnover
(rates of muscle protein synthesis and breakdown) could be used in support of a mechanism by which
the food/constituent could lead to an increase in muscle mass and/or muscle strength.
The scientiﬁc evaluation of health claims on muscle strength requires sufﬁcient characterisation
of the target population for which the claim is made and of the conditions of use for the claim. The
target population for the claim should be sufﬁciently characterised regarding physical ﬁtness and/or
age of the subjects, whenever these characteristics are thought to affect the relationship between the
intake of the food/constituent and the claimed effect. The conditions of use for the claim should clearly
indicate all aspects related to:
a) the consumption of the food constituent (e.g. the amount, the frequency of consumption, the
timing of consumption in relation to the physical exercise), and
b) the concomitant intervention(s) that are important/needed to achieve the claimed effect, as
appropriate (e.g. type/intensity/frequency/duration of concomitant training).
A claim on creatine in combination with resistance training and improvement in muscle strength
was evaluated by the Panel with a favourable outcome (EFSA NDA Panel, 2016b). The target
population for the claim was adults > 55 years of age who are engaged in regular resistance training.
The scientiﬁc assessment was based on the results of 10 human intervention studies provided by the
applicant and on evidence for a mechanism by which creatine could exert the claimed effect. The
human intervention studies investigated multiple outcome variables of muscle strength (e.g. 1RM
weight lifting (bench press), 1RM chest press, 1RM knee extension, 1RM biceps curl, 1RM leg press
and 1RM leg extension) in different combinations in order to assess upper and lower body muscle
strength using different protocols. Overall, the human intervention studies submitted provided
evidence for an effect of creatine consumed at doses of at least 3 g/day in combination with regular
resistance training (three times per week for several weeks) of moderate intensity on muscle strength
in adults 55 years of age and older. No such effect was observed when similar weekly doses of
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creatine were given on training days only (three times per week). The Panel also took into account the
plausible mechanism by which daily consumption of creatine in combination with resistance training
could improve muscle strength.
The recovery or restoration of muscle function (e.g. muscle strength, contraction) after
exercise is considered a beneﬁcial physiological effect. Human intervention studies investigating the
effect of a food/constituent consumed before (either acutely or chronically), during and/or after an
initial strenuous exercise bout on performance parameters at a subsequent exercise bout after a
recovery period are appropriate to assess these claims (e.g. repetitions-to-fatigue test re-test).
Subjective measures of (perceived) muscle fatigue/exertion or muscle soreness (e.g. validated
questionnaires13) may be used as supportive evidence in this context. Measures of skeletal muscle
glycogen stores, measures of muscle protein turnover (rates of muscle protein synthesis and
breakdown) and some measures of muscle structure (e.g. muscle damage, muscle tissue repair) can
provide support for a mechanism by which the food/constituent could exert the claimed effect.
A health claim related to glycaemic carbohydrates and faster recovery of normal muscle
function (contraction) after strenuous exercise was evaluated by the Panel with a favourable
outcome (EFSA NDA Panel, 2013). The scientiﬁc substantiation of this claim relied on consensus opinions
from authoritative bodies, which were based on a wealth of human intervention (efﬁcacy) studies,
human studies on methods used for measuring muscle glycogen stores, and mechanistic in vitro and
animal studies. The Panel also considered that the mode of action was well established. The target
population for this claim was individuals performing strenuous exercise. The conditions of use for this
claim were rather based on the amount of carbohydrates and consumption time relative to the exercise
which could increase glycogen re-synthesis in muscle and restore skeletal muscle glycogen stores.
A number of claims related to speciﬁc protein sources (e.g. bovine colostrum, casein protein
hydrolysates, whey protein), speciﬁc amino acids which are incorporated into proteins (e.g. BCAA, L-
glutamine) or speciﬁc constituents derived from protein amino acids (L-carnitine, L-carnosine) have
been evaluated by the Panel with an unfavourable opinion (Appendix A). The claimed effects were
growth or maintenance of muscle mass, maintenance of normal muscle function, faster recovery of
muscle function/strength/glycogen stores after exercise, faster recovery from muscle fatigue after
exercise and skeletal muscle tissue repair.
For the scientiﬁc substantiation of claims on the effects of speciﬁc protein sources/constituents on
outcome variables related to muscle mass and muscle function (e.g. muscle strength), human
intervention studies assessing the effect of a speciﬁc protein source/constituent against another
isonitrogenous protein source/constituent were considered as pertinent to the claim, whereas studies
controlling for energy only (e.g. using isocaloric carbohydrate sources as comparator) could not be
used for the scientiﬁc substantiation of these claims. Measures of whole body lean mass in
combination with measures of muscle strength were considered appropriate to assess changes in
muscle mass. For well-characterised protein sources/constituents, the Panel concluded that a cause
and effect relationship had not been established between the consumption of speciﬁc protein sources/
constituents and growth or maintenance of muscle mass over and above the well-established role of
protein on the claimed effect (i.e. beyond what could be expected from the consumption of mixed
dietary protein within the DRV when energy and other nutrient requirements are met; (EFSA NDA
Panel, 2012a); see also Section 4.1.1).
Two applications on citrulline malate and faster recovery from muscle fatigue after exercise
were evaluated by the Panel with an unfavourable opinion (EFSA NDA Panel, 2012b, 2014a). The
human intervention studies provided for the scientiﬁc substantiation of the claim assessed subjective
measures of muscle soreness after strenuous exercise, blood lactate concentrations during exercise
and/or perceived fatigue during exercise. Performance parameters were not assessed in those studies.
The Panel considered that, while there is consensus on the contribution of training in reducing blood
lactate concentrations during and after exercise and on delaying muscle fatigue during exercise, no
evidence was provided that lowering blood lactate through a dietary intervention can prevent or
alleviate loss of muscle function during exercise or can lead to a faster recovery from muscle fatigue
by contributing to the restoration of muscle function after exercise. The Panel also noted that there is
no consensus on the role of lactate in the recovery from muscle fatigue.
13 See the General scientiﬁc guidanceEFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2016a. General
scientiﬁc guidance for stakeholders on health claim applications EFSA Journal 2016;14(1):4367, 38 pp. https://doi.org/10.
2903/j.efsa.2016.4367., i.e. Annex C-Considerations on the validation of questionnaires and their use as outcome variables for
the scientiﬁc substantiation of health claims.
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4.2.2. Claims on physical performance and physical capacity
Physical performance is the ability to complete certain physical tasks. An increase in physical
performance refers to completion of a given physical task with higher intensity, and therefore faster or
with a higher power output. Measures of physical performance are obtained in the context of task-
limited (e.g. time spent to run/row/swim or cycle a predeﬁned distance) or time-limited (e.g. maximum
distance cycled in a predeﬁned time) physical activities. Improvement, maintenance or reduced loss of
physical performance is a beneﬁcial physiological effect for individuals performing physical exercise for
different reasons (e.g. athletes preparing for a competition or during a competition, individuals
engaged in recreational activities), but also for individuals performing common (non-exercise related)
physical tasks.
Physical capacity, on the other hand, refers to the exercise time to fatigue when exercising at
predeﬁned conditions (e.g. a given workload, intensity or speed). Exercise time to fatigue is an
appropriate measure of physical capacity. An increased physical capacity is a beneﬁcial physiological
effect for individuals performing physical exercise which is not limited by time or task (e.g. recreational
running, walking, swimming, cycling and ﬁtness training).
Although an increase in physical capacity (e.g. the time that an individual can exercise to fatigue at
a given workload, intensity or speed) may lead to an improvement in physical performance, measures
of physical capacity are not appropriate outcome variables for the scientiﬁc substantiation of claims on
physical performance and vice versa. An increase in physical capacity, however, could be associated to
an increase in physical performance and therefore measures of physical capacity could be used to
support an effect of the food/constituent on physical performance.
Claims on speciﬁc physiological effects (e.g. reduction in rated perceived exertion/effort during
exercise, enhancement of water absorption during exercise) which may lead to an improvement in
physical capacity and/or performance have been proposed and evaluated by the Panel. A claim related
to carbohydrate-electrolyte solutions and enhancement of water absorption during exercise (EFSA NDA
Panel, 2011h), and a claim related to caffeine (EFSA NDA Panel, 2011j) and the reduction in the rated
perceived exertion/effort during exercise, have been evaluated by the Panel with a favourable
outcome. For both food/constituents, a claim on increase/maintenance of endurance performance
(carbohydrate-electrolyte solutions and caffeine) and/or a claim on increased endurance capacity
(caffeine) were also evaluated by the Panel with a favourable outcome within the same scientiﬁc
opinion (Appendix A). The Panel considers that speciﬁc physiological effects such as the reduction in
the rated perceived exertion/effort during exercise or an enhancement of water absorption during
exercise could be the mechanisms by which a food/constituent could exert an effect on physical
capacity or performance. However, evidence that the food/constituent has an effect on direct
measures of physical capacity or physical performance should also be provided.
4.2.2.1. Claims on physical performance
The scientiﬁc evaluation of health claims on physical performance requires sufﬁcient
characterisation of the exercise or physical activity under evaluation, of the target population for which
the claim is made, and of the conditions of use for the claim. These aspects may be tightly linked to
knowledge (or hypotheses) on the mechanisms by which the food/constituent could exert the claimed
effect.
The exercise or physical activity under evaluation (e.g. the testing conditions under which the food/
constituent may affect performance) needs to be characterised by:
a) the mode/type of exercise or physical activity. The type of exercise (e.g. cycling,
running, swimming, weight-lifting) or physical activity (e.g. walking), and whether it is
intermittent (e.g. repeated bouts, sprints, repetitions maximum) or continuous (e.g. running
at constant speed, cycling at a given cadence) needs to be indicated;
b) the intensity/load expressed in relative terms using objective measures (e.g. %HRmax,
%HRR, %VO2max, %VO2R; %1RM, %MVC);
c) duration, as minutes of activity in each exercise session. For intermittent exercises, the
number and duration of exercise sets/intervals, and the number and duration of rest periods
within a session, should also be indicated.
Owing to the vast variety of exercise protocols that are being used to test physical performance in
humans, additional information may be required for their characterisation. For example, test trials (e.g.
a time-limited, self-paced maximal cycling ride) may be preceded by other trials of ﬁxed intensity and
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duration to increase harmonisation of the pretest conditions (EFSA NDA Panel, 2018). If that is the
case, the pretest physical exercise should also be described in terms of mode/type, intensity and
duration as accurately as possible. Duration and intensity of the exercise should be expressed
quantitatively (e.g. duration in minutes, intensity as %VO2max) rather than qualitatively (e.g. short
duration, high intensity).
The target population for the claim should be sufﬁciently characterised regarding ﬁtness status and/
or age whenever these characteristics are thought to affect the relationship between the intake of the
food/constituent and the claimed effect.
Outcome variables/methods of measurement of physical performance which may be appropriate for
the assessment of the claimed effect in humans in the context of a particular type of exercise or
physical activity should be indicated (e.g. time spent to run a certain distance, distance cycled during a
time trial).
As for the conditions of use, when the food/constituent should be consumed relative to the physical
performance test (e.g. before and/or during exercise), the duration of the intervention, and the need
of concomitant training, are important aspects to consider. In this context, training programs should
also be characterised in relation to the mode/type (e.g. resistance training; swimming), the intensity/
load (where appropriate), the duration of each session and the frequency (e.g. number of activity
sessions per day, week, or month).
Cycling, running, swimming or rowing time-trial tests (e.g. a sort of race where individuals try to
cover a predeﬁned distance as fast as possible) are task-limited physical activities that can be
used to assess physical performance both in the general population and in athletes practising such
sports. The time spent to cover a certain distance, either alone or in combination with the total/mean
work/power output developed during the time-trial test, is an appropriate outcome measure of
physical performance. The time spent to cover a certain distance depends on individual conditional
capacities, like resistance, speed, muscular power and strength, which can be modiﬁed (improved) by
training. Jumping height is critical for a successful performance in many sport activities, like basketball
or volleyball, and can be used as a measure of physical performance in the general population.
Throwing distance in javelin throw or shot put are also appropriate task-limited measures of physical
performance. However, since these are highly technical ﬁeld disciplines, the use of these outcomes is
limited to the evaluation of physical performance in javelin throwers or shot putter athletes.
Conversely, task (distance/work)-limited walking speed tests are appropriate for the substantiation of
health claims on reduced loss of physical performance in the elderly, whereas their use to assess
changes in physical performance in other population subgroups (e.g. physically competent children and
adults, athletes) is limited.
Physical performance can also be assessed in the context of time-limited physical activities as
the maximal distance covered by, e.g. cycling, running, swimming or rowing within a predeﬁned time,
either alone or in combination with the total/mean work/power output developed during the test.
The use of other task-limited or time-limited tests of physical performance, such as walking speed
or the number of chair-stands in a certain time, are more appropriate for the substantiation of health
claims on the improvement (i.e. reduced loss) of physical performance in the elderly.
Some of the outcome variables proposed for the substantiation of claims on physical performance
(e.g. changes in VO2max, increase muscle glycogen stores, changes in substrate oxidation, blood
lactate concentrations, muscle carnosine stores) are not direct measures of performance, but could be
used in support of a mechanism by which the food/constituent could exert the claimed effect.
A claim on creatine and increase in physical performance during short-term, high intensity, repeated
exercise bouts has been evaluated by the Panel with a positive outcome (EFSA NDA Panel, 2011k).
The scientiﬁc substantiation of the claim was based on a wealth of human intervention studies which
investigated the effects of different creatine doses, patterns of consumption and duration of the
supplementation on physical performance during continuous and intermittent physical activities of
variable intensity and duration in various population subgroups (men and women of different ages and
levels of training); on the results of two meta-analysis summarising the results of the above-mentioned
human studies; and on the well-established mechanism by which creatine could exert the claimed
effect. The conditions of use for the claim were established based on the results of the human
intervention studies (i.e. minimum effective daily dose). The target population was adults performing
high-intensity exercise. Conversely, the human studies provided did not show an effect of creatine
supplementation on measures of endurance capacity or endurance performance, and there was no
consensus on the role of creatine in increasing endurance capacity or endurance performance.
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A claim on b-alanine and increase in physical performance during short-duration, high intensity
exercise has been evaluated by the Panel with an unfavourable outcome (EFSA NDA Panel, 2014b).
Human intervention studies on the effects of b-alanine on measures of physical capacity (e.g. time to
exhaustion and/or total work done and/or physical working capacity at fatigue threshold) in the
context of time unlimited physical activities which did not report on any measures of physical
performance were excluded from the assessment. The main outcomes investigated in the remaining
studies were the time spent to complete a certain task (run, row, swim or cycle a predeﬁned distance)
and power output in time-limited (all-out or maximal effort) tasks lasting seconds. Overall, no effect of
b-alanine supplementation on measures of physical performance was found.
A claim on carbohydrate solutions and increase in physical performance during a high-intensity and
long-lasting physical exercise has been evaluated by the Panel with a favourable outcome (EFSA NDA
Panel, 2018). The applicant deﬁned high-intensity and long-lasting physical exercises as those being
performed at least at 65% of the VO2max, at maximal effort, or during a time-trial test for at least
60 min. The scientiﬁc substantiation of the claim was based on the results of four human intervention
studies conducted in non-fasting conditions after a standard meal, which were supported by the results
of four intervention studies conducted after an overnight fast and the results of two intervention studies
conducted under poorly speciﬁed nutritional conditions (e.g. at least a 4-h fast). In these studies,
trained participants underwent one or more exercise trials of ﬁxed intensity (generally ≥65% of the
VO2max or 70–80% of HRmax) and duration (overall lasting > 60 min), followed by an all-out test in
which performance was measured. Different types of exercise (e.g. cycling, running) were used for the
pretest and the test trials, which were either continuous, intermittent, or a combination of these (e.g. a
cycling trial before and during the test; four cycling trials of eight intermittent bouts followed by an all-
out maximal ride). Carbohydrate solutions (containing glucose, mixtures of glucose and fructose,
sucrose and/or maltodextrins) were consumed before and/or during the exercise session. The target
population for the claim was deﬁned as healthy trained adults performing high-intensity (at least at
65% of the VO2max) and long-lasting (at least 60 min) physical exercise.
A claim on caffeine and an increase in endurance performance has been evaluated by the
Panel with a positive outcome (EFSA NDA Panel, 2011j). The Panel took into account that most of the
human intervention studies provided using time- or task-limited exercise protocols lasting 60 min or
more (including a meta-analysis of ﬁve randomised controlled trials (RCTs) and three individual RCTs)
showed an effect of caffeine consumption on endurance performance at doses of at least 3 mg/kg
body weight administered at least 1 h prior to exercise, and after at least 1 day of caffeine withdrawal,
in habitual caffeine consumers.
4.2.2.2. Claims on physical capacity
The scientiﬁc evaluation of health claims on physical capacity requires sufﬁcient characterisation of
the claimed effect and of the target population for which the claim is made.
Physical capacity can be assessed in human intervention studies using several exercise protocols as
long as they are not task- or time-limited overall, so that subjects can exercise to fatigue. The
particular mode/type of exercise (e.g. cycling, running and swimming; single bout vs repeated bouts)
and the conditions in which physical capacity is tested (e.g. intensity of the exercise, speed, power
output) should be speciﬁed. The exercise time to fatigue under deﬁned conditions can be assessed by
using objective (e.g. cycling cadence, running speed) or self-reported (e.g. with a validated
questionnaire) measurements of physical fatigue. As for claims on physical performance, the target
population for the claim should be sufﬁciently characterised regarding ﬁtness status and/or age. The
amount and the time of consumption of the food/constituent relative to the exercise test (e.g. before
and/or during exercise) is an important aspect to consider when establishing conditions of use.
A claim on caffeine and an increase in endurance capacity has been evaluated by the Panel with a
favourable outcome (EFSA NDA Panel, 2011j). The Panel took into account that most of the human
intervention studies provided using no time-limited exercise protocols (including a meta-analysis of
23 RCTs evaluating 39 outcomes and two individual RCTs) showed an effect of caffeine consumption
on endurance capacity at doses of at least 3 mg/kg body weight administered at least one hour prior
to exercise, and after at least 12 h of caffeine withdrawal, in habitual caffeine consumers. The
Panel also considered that a plausible mechanism by which caffeine could exert the claimed effect is
through the reduction of perceived exertion during exercise, a claim which was evaluated in the same
scientiﬁc opinion with a positive outcome.
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Abbreviations
1RM one repetition maximum
BCAA branched-chain amino acids
DOMS delayed-onset muscle soreness
DRV Dietary Reference Values
HBM b-hydroxy b-methylbutyrate monohydrate
HRmax maximum heart rate
HRR heart rate reserve
KIC a-ketoisocaproic acid
MVC maximum voluntary contraction
NDA EFSA Panel on Nutrition, Novel Foods and Food Allergens
RCTs randomised controlled trials
RPE rating of perceived exertion
SOD superoxide dismutase
VO2max maximum oxygen consumption
VO2R VO2 reserve
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Appendix A – Health claims on muscle function and physical performance evaluated by the EFSA NDA Panel
Food constituent Claimed effect Outcome
Based on the
essentiality of
nutrients
Scope References
ATP Maintenance of normal muscle function Unfavourable – Art. 13(1) EFSA NDA Panel (2011i)
b-alanine Increase in physical performance during short-term high-intensity
exercise
Unfavourable – Art. 13(1) EFSA NDA Panel (2010d)
Increase in time to exhaustion Unfavourable –
Increase in physical performance during short-duration, high-
intensity exercise
Unfavourable – Art. 13(5) EFSA NDA Panel (2014b)
Bovine colostrum Improvement in exercise performance when combined with regular
training
Unfavourable – Art. 13(1) EFSA NDA Panel (2011l)
Increase in lean body mass when combined with resistance exercise Unfavourable –
Recovery following intense exercise Unfavourable –
BCAA Growth or maintenance of muscle mass Unfavourable – Art. 13(1) EFSA NDA Panel (2010g)
Attenuation of the decline in muscle power following exercise at
high altitude
Unfavourable –
Faster recovery from muscle fatigue after exercise Unfavourable –
Improvement of cognitive function after exercise Unfavourable –
Reduction in perceived exertion during exercise Unfavourable –
b-hydroxy b-
methylbutyrate
monohydrate (HBM)
alone or in combination
with a-ketoisocaproic
acid (KIC)
Reduction of muscle tissue damage during exercise Unfavourable – Art. 13(1) EFSA NDA Panel (2011m)
Increase in lean body mass Unfavourable –
Increase in muscle strength Unfavourable –
Increase in endurance performance Unfavourable –
Skeletal muscle tissue repair Unfavourable –
Faster recovery from muscle fatigue after exercise Unfavourable –
Caffeine Increase in physical performance during short-term high-intensity
exercise
Unfavourable – Art. 13(1) EFSA NDA Panel (2011j)
Increase in endurance capacity Favourable NO
Increase in endurance performance Favourable NO
Reduction in the rated perceived exertion/effort during exercise Favourable NO
Calcium Maintenance of normal muscle function (contraction) Favourable YES Art.13(1) EFSA NDA Panel (2009a)
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Food constituent Claimed effect Outcome
Based on the
essentiality of
nutrients
Scope References
Carbohydrate solutions Maintenance of physical performance during endurance exercise Unfavourable – Art. 13(5) EFSA NDA Panel (2014c)
Improvement of physical performance during a high-intensity and
long-lasting physical exercise
Favourable NO Art. 13(5) EFSA NDA Panel (2018)
Carbohydrate-
electrolyte solutions
Reduction in rated perceived exertion/effort during exercise Unfavourable – Art. 13(1) EFSA NDA Panel (2011h)
Enhancement of water absorption during exercise Favourable NO
Maintenance of endurance performance Favourable NO
Casein protein
hydrolysates
Growth or maintenance of muscle mass Unfavourable – Art. 13(1) EFSA NDA Panel (2011n)
Increase in endurance performance Unfavourable –
Faster recovery from muscle fatigue after exercise Unfavourable –
Citruline malate Faster recovery from muscle fatigue after exercise Unfavourable – Art. 13(5) EFSA NDA Panel
(2012b, 2014a)
Coenzyme Q10 Contribution to normal energy-yielding metabolism Unfavourable – Art. 13(1) EFSA NDA Panel (2010f)
Increase in endurance capacity and/or endurance performance Unfavourable –
Creatine Increase in physical performance during short-term, high intensity,
repeated exercise bouts
Favourable NO Art. 13(1) EFSA NDA Panel (2011k)
Increase in endurance capacity Unfavourable –
Increase in endurance performance Unfavourable –
Improvement in muscle strength (in combination with resistance
training)
Favourable NO Art. 13(5) EFSA NDA Panel (2016b)
L-carnitine Faster recovery from muscle fatigue after exercise Unfavourable – Art.13(1) EFSA NDA Panel (2011a)
Skeletal muscle tissue repair Unfavourable –
Increase in endurance capacity Unfavourable –
L-carnosine Increase in muscle power Unfavourable – Art.13(1) EFSA NDA Panel (2011b)
Increase in endurance capacity Unfavourable –
Glycaemic
carbohydrates
Recovery of normal muscle function (contraction) after strenuous
exercise
Favourable YES Art.13(5) EFSA NDA Panel (2013)
L-glutamine Growth or maintenance of muscle mass Unfavourable – Art.13(1) EFSA NDA Panel (2011c)
Faster restoration of muscle glycogen stores after strenuous
exercise
Unfavourable –
Skeletal muscle tissue repair Unfavourable –
Magnesium Maintenance of normal muscle function (contraction) Favourable YES Art.13(1) EFSA NDA Panel (2009c)
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Food constituent Claimed effect Outcome
Based on the
essentiality of
nutrients
Scope References
Potassium Maintenance of normal muscle function (contraction) Favourable YES Art.13(1) EFSA NDA Panel (2010h)
Protein Growth or maintenance of muscle mass Favourable YES Art.13(1) EFSA NDA Panel (2010a)
Ribose Faster recovery from muscle fatigue after exercise Unfavourable – Art.13(1) EFSA NDA Panel (2011d)
Sodium Maintenance of normal muscle function (contraction) Favourable YES Art.13(1) EFSA NDA Panel (2011g)
Sodium phosphate Increase in endurance performance Unfavourable – Art.13(1) EFSA NDA Panel (2011f)
Increase in endurance capacity Unfavourable –
Soy phosphatidyl
choline
Faster recovery from muscle fatigue after exercise Unfavourable – Art.13(1) EFSA NDA Panel (2010e)
Improvement of neuromuscular function Unfavourable –
Contribution to normal fat metabolism Unfavourable –
Superoxide dismutase
(SOD)
Reduction of muscle fatigue during exercise Unfavourable – Art.13(1) EFSA NDA Panel (2010b)
Taurine Maintenance of normal cardiac function Unfavourable – Art.13(1) EFSA NDA Panel
(2009b, 2011e)Maintenance of normal muscle function Unfavourable –
Delay in the onset of physical fatigue during exercise Unfavourable –
Whey protein Growth or maintenance of muscle mass Unfavourable – Art.13(1) EFSA NDA Panel (2010c)
Increase in lean body mass during energy restriction and resistance
training
Unfavourable –
Reduction of body fat mass during energy restriction and resistance
training
Unfavourable –
Increase in muscle strength Unfavourable –
Increase in endurance capacity during the subsequent exercise bout
after strenuous exercise
Unfavourable –
Skeletal muscle tissue repair Unfavourable –
Faster recovery from muscle fatigue after exercise Unfavourable –
BCAA: branched-chain amino acids.
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